Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2436578
Max Phase: Preclinical
Molecular Formula: C21H23F3N4O4
Molecular Weight: 452.43
Molecule Type: Small molecule
Associated Items:
ID: ALA2436578
Max Phase: Preclinical
Molecular Formula: C21H23F3N4O4
Molecular Weight: 452.43
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1cc(C(=O)N2CCC3(CCN(C(=O)Nc4ccc(OC(F)(F)F)cc4)C3)CC2)no1
Standard InChI: InChI=1S/C21H23F3N4O4/c1-14-12-17(26-32-14)18(29)27-9-6-20(7-10-27)8-11-28(13-20)19(30)25-15-2-4-16(5-3-15)31-21(22,23)24/h2-5,12H,6-11,13H2,1H3,(H,25,30)
Standard InChI Key: SSGWHCIZUQKWRQ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 452.43 | Molecular Weight (Monoisotopic): 452.1671 | AlogP: 4.04 | #Rotatable Bonds: 3 |
Polar Surface Area: 87.91 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.75 | CX Basic pKa: | CX LogP: 3.18 | CX LogD: 3.18 |
Aromatic Rings: 2 | Heavy Atoms: 32 | QED Weighted: 0.76 | Np Likeness Score: -1.82 |
1. Kato Y, Fuchi N, Saburi H, Nishimura Y, Watanabe A, Yagi M, Nakadera Y, Higashi E, Yamada M, Aoki T.. (2013) Discovery of 2,8-diazaspiro[4.5]decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension., 23 (21): [PMID:24035338] [10.1016/j.bmcl.2013.08.054] |
Source(1):